Tore Bach-Gansmo MD,PhD, Presenter: Nothing to Disclose

Rimma Danielsson, Abstract Co-Author: Nothing to Disclose

Trond Velde Bogsrud, Abstract Co-Author: Nothing to Disclose

Anne Fangberget, Abstract Co-Author: Nothing to Disclose

Derek Tobin, Abstract Co-Author: Nothing to Disclose

The aim of the study was to evaluate initial efficacy and safety of a novel 99mTc labelled agent developed by GE Healthcare for imaging angiogenesis in patients with breast cancer.

Sixteen subjects with breast cancer and 4 subjects with non-malignant lesions were enrolled in the study. Each subject received 75mg of 99mTc labelled NC100692 with an average activity of 694 MBq. NC100692 is a small peptide with high affinity for the avb3 integrin receptor which is upregulated specifically on endothelial cells during the angiogenic process. Planar and SPECT imaging were performed between 40 min and 2½ hours after injection of the agent.

Twenty malignant lesions were seen on mammography and/or ultrasound and confirmed as malignant by histopathology. Nineteen of these lesions (diameter 5-40 mm) were detected using scintigraphic imaging with 99mTc-NC100692 Injection. The only lesion not identified by conventional scintigraphic imaging had a diameter of 6 mm and was located close to the breast wall. The lesion was, however, seen using a cadmium-zinc-teluride (LUMA-GEM) camera, using breast compression, confirming that lesion-related uptake of 99mTc-NC100692 occurred. No serious or troublesome adverse events were recorded.

The data suggest that scintigraphy with 99mTc-NC100692 is effective in detecting breast cancer without any safety concern.

D.T.: D.Tobin is emplyed by GE Healthcare

Bach-Gansmo, T, Danielsson, R, Bogsrud, T, Fangberget, A, Tobin, D, Safety and Efficacy of a New 99mTc-labelled Peptide Demonstrating Areas of Angiogenesis Related to Malignancy.  Radiological Society of North America 2005 Scientific Assembly and Annual Meeting, November 27 - December 2, 2005 ,Chicago IL. http://archive.rsna.org/2005/4417093.html